loading
4 D Molecular Therapeutics Inc stock is traded at $7.99, with a volume of 134.98K. It is down -4.76% in the last 24 hours and down -6.64% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$8.41
Open:
$8.41
24h Volume:
134.98K
Relative Volume:
0.17
Market Cap:
$400.33M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.436
EPS:
-3.28
Net Cash Flow:
$-78.56M
1W Performance:
-0.12%
1M Performance:
-6.64%
6M Performance:
-68.15%
1Y Performance:
-32.97%
1-Day Range:
Value
$7.90
$8.48
1-Week Range:
Value
$7.90
$9.1799
52-Week Range:
Value
$7.32
$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Name
4 D Molecular Therapeutics Inc
Name
Phone
(510) 505-2680
Name
Address
5858 HORTON STREET #455, EMERYVILLE
Name
Employee
201
Name
Twitter
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
FDMT 7.99 400.33M 20.72M -100.84M -78.56M -3.28
VRTX 447.53 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.03 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.31 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.73 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.47 24.49B 3.30B -501.07M 1.03B 11.54

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-07-24 Resumed Goldman Buy
Oct-26-23 Initiated RBC Capital Mkts Outperform
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Oct-18-23 Upgrade Leerink Partners Market Perform → Outperform
Jul-05-23 Initiated Chardan Capital Markets Buy
Jan-30-23 Initiated BMO Capital Markets Outperform
Nov-18-22 Initiated H.C. Wainwright Buy
Nov-15-22 Upgrade Goldman Neutral → Buy
Aug-12-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jun-22-22 Initiated Jefferies Buy
Jan-04-22 Initiated SVB Leerink Outperform
Jan-05-21 Initiated BofA Securities Buy
Jan-05-21 Initiated Evercore ISI Outperform
Jan-05-21 Initiated Goldman Neutral
View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

pulisher
08:04 AM

4D Molecular Therapeutics (NASDAQ:FDMT) Earns Underweight Rating from Analysts at Morgan Stanley - MarketBeat

08:04 AM
pulisher
Nov 18, 2024

FY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

4D Molecular Therapeutics’ Positive Q3 and Strategic Advances - TipRanks

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Increases Stake in 4D Molecular Ther - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Janus Henderson Group PLC's Strategic Adjustment in 4D Molecular Therapeutics Inc Holdings - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Analyst Expectations For 4D Molecular Therapeutics's Future - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

4D Molecular Sets Major Conference Schedule: Jefferies, Evercore & OIS XIV Appearances | FDMT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 14, 2024
pulisher
Nov 13, 2024

4D Molecular Therapeutics Inc Reports Q3 2024 EPS of $(0.79) and Revenue of $3,000 - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

4D Molecular Reports Positive AMD Trial Data, $551M Cash Position Funds Operations to 2027 | FDMT Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.9 By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 12, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.9 - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

4D Molecular Therapeutics Inc. (FDMT) Quarterly 10-Q Report - Quartz

Nov 12, 2024
pulisher
Nov 12, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus PT from Analysts - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace

Nov 12, 2024
pulisher
Nov 07, 2024

X-Linked Retinitis Pigmentosa Clinical Trials 2024: FDA - openPR

Nov 07, 2024
pulisher
Nov 07, 2024

Goldman Sachs Group Inc's Strategic Reduction in 4D Molecular Th - GuruFocus.com

Nov 07, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com

Nov 05, 2024
pulisher
Oct 30, 2024

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat

Oct 29, 2024
pulisher
Oct 27, 2024

Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan

Oct 25, 2024
pulisher
Oct 23, 2024

nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts

Oct 22, 2024
pulisher
Oct 18, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe

Oct 16, 2024
pulisher
Oct 14, 2024

Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

4D Molecular Therapeutics Inc (FDMT)’s Day in Review: Closing at 9.17, Up by 5.04 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Prospect Capital Corp [PSEC] Investment Guide: What You Need to Know - Knox Daily

Oct 14, 2024
pulisher
Oct 12, 2024

4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is A Good Option To Consider - Stocks Register

Oct 12, 2024
pulisher
Oct 12, 2024

Looking For A Top Momentum Stock? Check Out Service Properties Trust (NASDAQ: SVC) - Stocks Register

Oct 12, 2024
pulisher
Oct 12, 2024

Metrics That Matter About Roper Technologies Inc (NASDAQ: ROP) - Stocks Register

Oct 12, 2024
pulisher
Oct 12, 2024

FTAI Infrastructure Inc (NASDAQ: FIP) Is A Blank Check For Growth - Stocks Register

Oct 12, 2024
pulisher
Oct 09, 2024

This trade activity should not be overlooked: 4D Molecular Therapeutics Inc (FDMT) - SETE News

Oct 09, 2024
pulisher
Oct 08, 2024

4D Molecular Therapeutics Inc (FDMT)’s stock decline to 9.26 per share - US Post News

Oct 08, 2024
pulisher
Oct 08, 2024

4D Molecular Therapeutics Inc (FDMT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

4D Molecular Therapeutics stock hits 52-week low at $9.41 By Investing.com - Investing.com UK

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -3.58, Closing at 9.97 - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Cantor Fitzgerald Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Neutral from an Overweight - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Dimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Oct 07, 2024
pulisher
Oct 04, 2024

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.8%What's Next? - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy FailureI'm Not So Sure - Seeking Alpha

Oct 04, 2024
pulisher
Oct 04, 2024

4D Molecular Therapeutics, Inc. Is Being Investigated For Possib - WICZ

Oct 04, 2024
pulisher
Oct 04, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Squarepoint Ops LLC - MarketBeat

Oct 04, 2024

4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):